Rod-cone dystrophy
RDH12-related retinal dystrophies are potential candidates for gene therapy
Roibeard O’hEineachain
Published: Monday, April 1, 2019
Retinopathies resulting from mutations in the gene for the enzyme retinal dehydrogenase (RDH12) mainly include severe, early-onset rod-cone dystrophies. Because this disease progresses gradually and small areas of the retina are retained late into the disease, there is a broad window of opportunity for gene therapy, according to Bart Leroy MD, PhD, Ghent University Hospital, Ghent, Belgium.
“Because of those normal areas, there is a window of opportunity to treat these patients,” Dr Leroy told the 18th EURETINA Congress in Vienna, Austria.
Bart Leroy MD, PhD